{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/common-cold/goals-outcome-measures/qipp-options-for-local-implementation/","result":{"pageContext":{"chapter":{"id":"0a34aff3-ba2e-5669-b5db-838f0f362dcf","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation","depth":2,"htmlHeader":"<!-- begin field 7399154b-ec5d-40a7-b33c-e03d81d81eb3 --><h2>QIPP - Options for local implementation</h2><!-- end field 7399154b-ec5d-40a7-b33c-e03d81d81eb3 -->","summary":null,"htmlStringContent":"<!-- begin item f396306c-7002-414f-aded-77dc048d65ff --><!-- begin field 6b2e3b27-516f-40fc-814f-dc39884d5537 --><ul><li><strong>Non-steroidal anti-inflammatory drugs (NSAIDs)</strong><ul><li>Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (e.g. older patients).</li><li>If initiating an NSAID is obligatory, use ibuprofen (1200 mg per day or less) or naproxen (1000 mg per day or less). Use the lowest effective dose and the shortest duration of treatment necessary to control symptoms.</li><li>Review patients currently prescribed NSAIDs. If continued use is necessary, consider changing to ibuprofen (1200 mg per day or less) or naproxen (1000 mg per day or less).</li><li>Review and, where appropriate, revise prescribing of etoricoxib to ensure it is in line with MHRA advice and the NICE clinical guideline on osteoarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/common-cold/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/common-cold/references/\">NICE, 2014</a>].</li><li>Co-prescribe a proton pump inhibitor (PPI) with NSAIDs for people with osteoarthritis, rheumatoid arthritis, or low back pain (for people over 45 years) in accordance with NICE guidance.</li><li>Take account of drug interactions when co-prescribing NSAIDs with other medicines (see Summaries of Product Characteristics). For example, co-prescribing NSAIDs with ACE inhibitors or angiotensin receptor blockers (ARBs) may pose particular risks to renal function; this combination should be especially carefully considered and regularly monitored if continued.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/common-cold/references/\">NICE, 2016</a>]</p><!-- end field 6b2e3b27-516f-40fc-814f-dc39884d5537 --><!-- end item f396306c-7002-414f-aded-77dc048d65ff -->","topic":{"id":"9b78695c-3c64-5770-bf35-1ee5cf2cb29f","topicId":"5aee85d5-d8d1-479b-bfa3-a30835b97d6e","topicName":"Common cold","slug":"common-cold","lastRevised":"Last revised in August 2016","chapters":[{"id":"2d71e136-2d58-5131-b317-e17dfa10407a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"68f3d785-7f34-53dc-8693-fac9f8cf0b83","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"80ffc4ec-68ee-5b3c-85de-9b0b2c0727cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"13da7724-388f-5083-87a4-d197fad621d3","slug":"changes","fullItemName":"Changes"},{"id":"f8e94edd-fbab-509e-a4a6-bcaeaee3a12e","slug":"update","fullItemName":"Update"}]},{"id":"845c4165-0e4b-54b7-ad0d-4a3f8ce0dba1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58640184-7105-5c0b-ba03-9ac3c8039df6","slug":"goals","fullItemName":"Goals"},{"id":"b7861ff1-501e-5737-93f3-92d5e0dd1b85","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8de0aa85-b6cc-5f52-b748-4ffd3122e588","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8c040833-f111-5821-a361-8c6e8971d947","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0a34aff3-ba2e-5669-b5db-838f0f362dcf","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37093313-70f3-5f75-91f7-5be0831b32fb","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"eaa30267-8e53-5abf-8ad1-72db861b9f26","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"82740581-ed8b-5193-99f7-b233c7b7168b","slug":"definition","fullItemName":"Definition"},{"id":"0c9cc525-5128-5e46-a30e-79addf37388d","slug":"complications","fullItemName":"Complications"},{"id":"97ad0093-c0b4-5459-bcc3-8075819fe57e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"619eae6e-4425-5457-b95d-3e0fe3df38af","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"0e772b83-eb60-572c-8aba-eda986114860","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"de4542d4-eadb-58d2-8a3e-518b0f5db16d","slug":"diagnosis-in-adults-older-children","fullItemName":"Diagnosis in adults and older children"},{"id":"2065bcd2-a2dd-57b9-a7a7-68cc0f02dd4b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"acb6f0c8-1362-53a1-a5c6-2c88f6dcd884","slug":"diagnosis-in-younger-children-infants","fullItemName":"Diagnosis in younger children and infants"}]},{"id":"5671b781-6df7-562c-bcc5-4512a4c9e87b","fullItemName":"Management","slug":"management","subChapters":[{"id":"918d4e1d-04ea-55d6-921d-1fb60d9ef655","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"6c968d83-9ed7-5f48-9826-507f18c0164c","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"edbddcd1-73e3-5ed4-bdf1-bafa5f1f1ba4","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"2791a821-42bd-565f-ac20-bd44ad4ede92","slug":"ibuprofen","fullItemName":"Ibuprofen"}]},{"id":"2977772c-75a3-5d12-904f-1f0656c66b16","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c5ceeaed-a580-5e23-a897-dc5e657814c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0aa676f7-343f-5fcc-b5ae-cbdff070eb86","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c4da17f2-12fb-59ac-be32-b10d7da360b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0f82fd8b-82f4-5d12-8c6f-044d21628edc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"881feb2e-6862-57b2-9c84-650136d4604e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"23a8e26b-fd6f-5bce-bd0f-169e08be2c98","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d6105ea0-66a6-5bd6-9d2c-edc57bdc708d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"845c4165-0e4b-54b7-ad0d-4a3f8ce0dba1","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}